TP A2: Expression profiling based drug design in epidermolysis bullosa acquisita
Epidermolysis bullosa aquisita is an autoimmune blistering disease, which is characterized by autoantibodies against COL VII. Despite of consequent immunosuppressive treatment, patients show a largely increased mortality. Consequently, new therapeutic strategies are urgently required. 23 natural compounds were investigated and 7 showed modulating effects on neutrophil chemotaxis, 5 showed effects on the ROS release and one additionally on CD62L shedding. We now aim to investigate these effects in an in vivo model in order to confirm beneficial effect of the substances and to find a new treatment strategy in autoimmune blistering diseases.
- Projects
- Projects
- TP A1 - B cell metabolism
- TP A2 - Expression profiling based drug design in EBA
- TP A3 -Differential roles and cell type specific effects of IL-17A and IL-17F in EBA
- TP A4 - Anti-laminin 322 mucous membrane pemphigoid
- TP A5 - C5a/C5aR in autoantibody induction
- TP A6 - Effects of immune-complexes with sialylated IgG antibodies...
- TP A7 - The effect of neutrophil extracellular traps (NETs) on human neutrophils in vitro
- TP B1 - Novel pemphigus animal model
- TP B2 - Autoimmunity alters the T cell receptor repertoire ...
- TP B3 - Metabolomics in autoimmunity
- TP B4 - Organotropism of leukocyte migration
- TP B6 - Pathomechanisms in experimental Systemic Sclerosis
- Associated projects
- MD projects
- Associated MD projects
- Concluded projects
- Projects